Safety Of VIRACEPT® 625mg Administered To HIV-Infected Women During Pregnancy

PHASE4CompletedINTERVENTIONAL
Enrollment

16

Participants

Timeline

Start Date

March 31, 2006

Primary Completion Date

November 30, 2007

Study Completion Date

November 30, 2007

Conditions
HIV Infection
Interventions
DRUG

Nelfinavir mesylate, 625 mg

Nelfinavir 625 mg \[dosed orally as 1250 mg BID (two 625 mg tablets given orally BID)\] plus Combivir (lamivudine 150 mg plus zidovudine 300 mg BID dosed orally) administered with food. Subjects will start treatment at their baseline visit. Subjects will be treated for up to 26 weeks during pregnancy plus 6 weeks postpartum.

Trial Locations (6)

19410

Pfizer Investigational Site, Philadelphia

32209

Pfizer Investigational Site, Jacksonville

33136

Pfizer Investigational Site, Miami

48201

Pfizer Investigational Site, Detroit

70006

Pfizer Investigational Site, Metairie

M5G 2N2

Pfizer Investigational Site, Toronto

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Pfizer

INDUSTRY

NCT00246610 - Safety Of VIRACEPT® 625mg Administered To HIV-Infected Women During Pregnancy | Biotech Hunter | Biotech Hunter